巨细胞动脉炎超声晕征早期变化与临床特征的关系
研究纳入345例疑似巨细胞动脉炎(GCA)患者,在启动糖皮质激素治疗7天内行颞动脉和腋动脉超声。结果发现颞动脉晕征与下颌跛行、视觉症状等缺血表现相关,且其大小在治疗7天内持续缩小,但腋动脉晕征未缩小,基线晕征不能预测后续缺血事件。
要点
- 颞动脉晕征与下颌跛行和视觉症状等缺血表现相关
- 糖皮质激素治疗7天内颞动脉晕征大小持续缩小,腋动脉无变化
- 基线晕征不能预测随访期间新发缺血事件
核心结论
- 新诊断GCA中颞动脉晕征与缺血特征相关,且其大小在糖皮质激素治疗后缩小,支持其作为早期疾病活动度标志物。
研究设计与样本
- 国际队列中疑似GCA患者,在启动糖皮质激素7天内行颞动脉和腋动脉超声,比较临床特征并横断面分析晕征厚度。
- 共345例有6个月随访数据的患者纳入分析,其中226例(65.5%)诊断为GCA。
主要发现
- 下颌跛行和视觉症状在晕征阳性患者中更常见(P=0.018和P=0.003)。
- 体格检查异常与同侧晕征存在显著关联(P<0.05)。
- 超声发现狭窄或闭塞对GCA诊断无贡献。
- 治疗7天内颞动脉晕征大小持续缩小(每患者最大晕征:r=-0.30,P=0.001;所有晕征:r=-0.23,P<0.001),腋动脉无显著变化(P>0.05)。
- 基线晕征不能预测随访期间发生的缺血事件。
临床怎么用
- 颞动脉晕征可用于支持GCA诊断并作为早期疾病活动度标志物。
- 糖皮质激素治疗后短期内颞动脉晕征缩小,可用于监测治疗反应。
- 腋动脉晕征短期不缩小,判读时需注意。
局限性
- 基线晕征未能预测后续缺血事件,其预后价值有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the ultrasound characteristics with clinical features, final diagnosis and outcome; and to evaluate the halo size following glucocorticoid treatment in patients with newly diagnosed GCA. METHODS: Patients with suspected GCA, recruited from an international cohort, had an ultrasound of temporal (TA) and axillary (AX) arteries performed within 7 days of commencing glucocorticoids. We compared differences in clinical features at disease presentation, after 2 weeks and after 6 months, according to the presence or absence of halo sign. We undertook a cross-sectional analysis of the differences in halo thickness using Pearson's correlation coefficient (r) and Analysis of Variance (ANOVA). RESULTS: A total of 345 patients with 6 months follow-up data were included; 226 (65.5%) had a diagnosis of GCA. Jaw claudication and visual symptoms were more frequent in patients with halo sign (P =0.018 and P =0.003, respectively). Physical examination abnormalities were significantly associated with the presence of ipsilateral halo (P <0.05). Stenosis or occlusion on ultrasound failed to contribute to the diagnosis of GCA. During 7 days of glucocorticoid treatment, there was a consistent reduction in halo size in the TA (maximum halo size per patient: r=-0.30, P =0.001; and all halos r=-0.23, P <0.001), but not in the AX (P >0.05). However, the presence of halo at baseline failed to predict future ischaemic events occurring during follow-up. CONCLUSION: In newly diagnosed GCA, TA halo is associated with the presence of ischaemic features and its size decreases following glucocorticoid treatment, supporting its early use as a marker of disease activity, in addition to its diagnostic role.
引用
- Ponte C, Serafim AS, Monti S, et al. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology (Oxford). 2020. PMID: 32393983. doi:10.1093/rheumatology/keaa196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。